πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

444 results for β€œOlogy” Clear

  1. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Advanced Breast Cancer

    phase 2 small molecule completed

    1 trial

  2. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2-positive Breast Cancer

    phase 2 small molecule completed

    1 trial

  3. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  4. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    GastroEsophageal Cancer

    phase 2 small molecule active

    1 trial

  5. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Metastatic Prostate Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  6. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Anatomic Stage I Breast Cancer

    phase 2 small molecule active

    1 trial

  7. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  8. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2 Amplified Breast Cancer

    phase 2 small molecule completed

    1 trial

  9. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Early Stage HER2+ Breast Cancer

    phase 2 small molecule completed

    1 trial

  10. Olumiant 2 mg film-coated tablets, Olumiant 4 mg film-coated tablets

    Pari Pharma GmbH

    -women with an inflammatory HCA proven at histology and with at least one inflammatory HCA of more than 5 cm. -male with at least one inflammatory HCA proven at histology whatever the size and considered as non resectable by the multidisciplinary tumor board

    phase 2 small molecule active

    1 trial

  11. Onvansertib

    Cardiff Oncology

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  12. Onvansertib

    Cardiff Oncology

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  13. Onvansertib

    Cardiff Oncology

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    2 trials

  14. Onvansertib

    Cardiff Oncology

    Small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. Onvansertib

    Cardiff Oncology

    Breast Cancer

    phase 2 small molecule active

    1 trial

  16. Onvansertib

    Cardiff Oncology

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  17. Onvansertib

    Cardiff Oncology

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  18. Onvansertib

    Cardiff Oncology

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

  19. PEG-IFNΞ±

    Vir Biotechnology

    Chronic Hepatitis B Virus Infection

    phase 2 mab active

    1 trial

  20. POMALIDOMIDE, POMALIDOMIDE, POMALIDOMIDE, POMALIDOMIDE, DARZALEX 1800 mg solution for injection, DEXAMETHASONE, DEXAMETHASONE

    Ology Bioservices Ireland LTD

    Relapsed/refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  21. PTR-01

    BridgeBio Oncology Therapeutics

    Recessive Dystrophic Epidermolysis Bullosa

    phase 2 small molecule completed

    1 trial

  22. PYX-201

    Pyxis Oncology

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  23. Paclitaxel

    Cardiff Oncology

    Carcinosarcoma

    phase 2 small molecule active

    1 trial

  24. Paclitaxel

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources